NewAmsterdam Pharma Announces Inducement Grants Under Nasdaq Rule 5635(c)(4)

NAARDEN, the Netherlands and MIAMI, Sept. 06, 2024 — NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage clinical biopharmaceutical enterprise, has announced the approval of inducement share options for three newly appointed non-executive employees. The decision was made by the Compensation Committee of NewAmsterdam's Board of Directors and involves a total of 111,000 of the company's ordinary shares. This move aims to incentivize the new hires to join the company, aligning with the guidelines of the NewAmsterdam Pharma Company N.V. 2024 Inducement Plan (the “2024 Inducement Plan”) and following Nasdaq Listing Rule 5635(c)(4).

The granted share options are set at an exercise price of $15.91 per share, which corresponds to the closing market price on the Nasdaq Stock Market of the company’s ordinary shares on September 3, 2024, the date when the grant was made. The vesting schedule for these options spans over four years, with 25% of the shares vesting after one year from the vesting commencement date. The remaining shares will vest equally on a monthly basis over the subsequent 36 months, contingent on the employees’ continued service with NewAmsterdam.

The options are governed by the stipulations of both the 2024 Inducement Plan and an option award agreement specific to the grant.

NewAmsterdam Pharma (Nasdaq: NAMS) is dedicated to improving patient outcomes in populations suffering from metabolic diseases where existing treatments are either inadequate or not well tolerated. The company focuses on developing safe, well-tolerated, and convenient therapies for lowering low-density lipoprotein cholesterol (LDL-C). NewAmsterdam is currently conducting multiple phase 3 clinical trials to evaluate obicetrapib, an oral, low-dose, once-daily CETP inhibitor. This drug is being tested both as a standalone treatment and in combination with ezetimibe as adjunct therapy for patients at risk of cardiovascular disease (CVD) with elevated LDL-C levels who have not responded well to existing therapies.

NewAmsterdam aims to address a significant unmet need in the market by providing an effective LDL-lowering treatment that complements statin therapy. The company’s research and development efforts are focused on offering a therapeutic solution that is both safe and well-tolerated, thereby improving patient adherence and outcomes.

By continuously exploring innovative treatments, NewAmsterdam strives to make a meaningful impact on the lives of patients at risk of cardiovascular diseases. The company’s commitment to excellence is reflected in its rigorous clinical trial processes and its focus on addressing gaps in current medical treatments.

In summary, NewAmsterdam Pharma is making strides in the field of cardiovascular health through its targeted research and strategic employee incentives. The recent approval of inducement share options for new hires underscores the company's commitment to attracting top talent to drive its mission forward. By continuing to develop and test novel therapies, NewAmsterdam aims to provide better treatment options for patients with elevated LDL-C levels, ultimately improving patient care and outcomes in the realm of cardiovascular disease.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!